Archive for December 2010
A true Markov model for sleep disturbance
Diack C., Ackaert O., Ploeger B., Graaf P.v.d., Gurrell R., Ivarsson M. and Fairman D., A true Markov model for sleep disturbance. PAGE.(2010). [Link to publication]
Read MoreA novel integrated RNAi/viral dynamics systems pharmacology model
Maanen E. v., Brady K., Steeg T.v. and Graaf P.v.d., A novel integrated RNAi/viral dynamics systems pharmacology model to predict clinical efficacy of viral vector delivery of siRNA for the treatment of HCV. Noordwijkerhout.(2010)
Read MoreDrug effects on the Cardiovascular system
Snelder N., Ploeger B., Danhof M., Stanski D., Rigel D., Webb R., Feldman D. and Luttringer O., Drug effects on the Cardiovascular system – development of a mechanism-based pharmacodynamic model to improve translational drug research. Noordwijkerhout.(2010)
Read MoreA population PD model for effects of the cytostatic drugs Irinotecan and Temozolomide on Rh18 rabdomyosarcoma xenografts in mice
Jongh J.d. and Ploeger B., A population PD model for effects of the cytostatic drugs Irinotecan and Temozolomide on Rh18 rabdomyosarcoma xenografts in mice. Noordwijkerhout.(2010).
Read MoreClinical impact of genetic polymorphisms observed in the pharmacokinetics of the novel PPAR agonist, Sipoglitazar
Stringer F., Jongh J.d, Ploeger B., Scott G., Urquart R. and Danhof M., Clinical impact of genetic polymorphisms observed in the pharmacokinetics of the novel PPAR agonist, Sipoglitazar. Noordwijkerhout.(2010)
Read MoreAssessment of the Potential for Displacement Interactions with Sugammadex
Zwiers A., Heuvel M.v.d., Smeets J. and Rutherford S., Assessment of the Potential for Displacement Interactions with Sugammadex: A Pharmacokinetic-Pharmacodynamic Modelling Approach, Clin Drug Investig, 10(10): 11584730-000000000, 2010. [Link to publication]
Read MoreEffect of altered AGP plasma binding
Steeg T.J.v., Krekels E.H., Freijer J., Danhof M. and Lange E.C.d., Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)), J Pharm Sci., 99(5): 2511-2520., 2010. [Link to publication]
Read MoreMarginal increase of sunitinib exposure
Erp N.P.v., Baker S.D., Zandvliet A.S., Ploeger B.A., Hollander M.d., Chen Z., Hartigh J.d., Konig-Quartel J.M., Guchelaar H.J. and Gelderblom H., Marginal increase of sunitinib exposure by grapefruit juice, Cancer Chemother Pharmacol, 29: 29, 2010.
Read MoreEstimation of binding rate constants
Benson N., Snelder N., Ploeger B., Napier C., Sale H., Birdsall N.J., Butt R.P. and Graaf P.H.v.d., Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetine, Br J Pharmacol., 160(2): 389-398., 2010. [Link to publication]
Read MoreModeling of alpha interferon response
Benson N., Jongh J.d, Duckworth J.D., Jones H.M., Pertinez H.E., Rawal J.K., Steeg T.J. v. and Graaf P.H.v.d., Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice, Antimicrob Agents Chemother., 54(3): 1179-1185. Epub 2009 Dec 1122., 2010. [Link to publication]
Read More